289 related articles for article (PubMed ID: 14571412)
1. Immunotherapy for prostate cancer.
Fong L; Small EJ
Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for prostate cancer.
Fong L; Small EJ
Curr Urol Rep; 2006 May; 7(3):239-46. PubMed ID: 16630528
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for prostate cancer.
Fong L; Small EJ
Curr Oncol Rep; 2007 May; 9(3):226-33. PubMed ID: 17430695
[TBL] [Abstract][Full Text] [Related]
4. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.
Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S
Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599
[TBL] [Abstract][Full Text] [Related]
6. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
7. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
[TBL] [Abstract][Full Text] [Related]
9. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
10. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles.
Nelson PS
Ann N Y Acad Sci; 2002 Dec; 975():232-46. PubMed ID: 12538168
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
12. [Cell therapy and prostate cancer].
Eymard JC; Bernard J
Bull Cancer; 2003; 90(8-9):734-43. PubMed ID: 14609763
[TBL] [Abstract][Full Text] [Related]
13. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
14. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
[TBL] [Abstract][Full Text] [Related]
16. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
17. CD8
Shore ND; Morrow MP; McMullan T; Kraynyak KA; Sylvester A; Bhatt K; Cheung J; Boyer JD; Liu L; Sacchetta B; Rosencranz S; Heath EI; Nordquist L; Cheng HH; Tagawa ST; Appleman LJ; Tutrone R; Garcia JA; Whang YE; Kelly WK; Weiner DB; Bagarazzi ML; Skolnik JM
Mol Ther; 2020 May; 28(5):1238-1250. PubMed ID: 32208168
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues.
Cunha AC; Weigle B; Kiessling A; Bachmann M; Rieber EP
Cancer Lett; 2006 May; 236(2):229-38. PubMed ID: 16046056
[TBL] [Abstract][Full Text] [Related]
19. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Slovin SF
Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
[TBL] [Abstract][Full Text] [Related]
20. Target antigens for prostate cancer immunotherapy.
Saffran DC; Reiter RE; Jakobovits A; Witte ON
Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
